Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Renal Insufficiency 1Paraproteinemias 1Osteolysis 1Multiple Myeloma 1Hypercalcemia 1Hematologic Neoplasms 1Fractures, Spontaneous 1Bone Diseases, Metabolic 1Anemia 1Amyloidosis 1

Interventions

Epoetin Alfa 10Darbepoetin alfa 4Therapeutics 2Filgrastim 2Ferric Oxide, Saccharated 2Cyclophosphamide 2Busulfan 2venetoclax 1trametinib 1ruxolitinib 1reolysin 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1fludarabine phosphate 1fludarabine 1ferrous sulfate 1ferric gluconate 1epoetin beta 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × ARQ 197 × Plasma cell × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡